Tumor Biology

, Volume 35, Issue 6, pp 5607–5612 | Cite as

Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population

  • Zhangyong Hu
  • Zhipeng Zhou
  • Guolian Xiong
  • Yali Wang
  • Yi Lai
  • Lan Deng
  • Jinliang Yang
Research Article


Cyclin D1, encoded by the gene CCND1, is a regulatory protein in the cell cycle transition from G1 phase to S phase. A common polymorphism (G870A) in the exon 4 of CCND1 gene affects splicing of the CCND1 transcript and may cause uncontrollable cellular growth. Therefore, the CCND1 G870A polymorphism may influence an individual’s susceptibility to the development of certain tumors. The present study was performed to test the association between G870A polymorphism in the CCND1 gene and hepatocellular carcinoma (HCC) risk in a Chinese population. We extracted the peripheral blood samples from 220 patients with HCC and 220 age- and gender-matched healthy controls. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis and direct DNA sequencing were performed to detect the polymorphism. The CCND1 genotype distribution among HCC patients was not significantly different from that among healthy controls (P = 0.08). Compared with the wild-type GG genotype, neither the variant AA genotype nor the variant genotypes containing the A allele were associated with risk of HCC. However, stratification analysis by HBV carrier status revealed that the variant genotypes containing the A allele were associated with a significantly increased risk of HCC among HBsAg-positive individuals (adjusted OR = 3.87; 95 % CI = 1.12, 13.30). These results suggest that the CCND1 G870A polymorphism may increase the risk of HBV-related HCC in the Chinese population.


Hepatocellular carcinoma Cyclin D1 Polymorphism Case–control study 



Cyclin D1


Odds ratio


Confidence interval


Polymerase chain reaction-restriction fragment length polymorphism


Single nucleotide polymorphisms


Hardy–Weinberg equilibrium


Conflicts of interest



  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–63.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen CJ, Chen DS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology. 2002;36:1046–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 2002; 35 (5 Suppl.2): S79–85.Google Scholar
  6. 6.
    Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005;42:846–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005;48:10–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans. 2010;38:217–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Callender T, El-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer. 1994;74:152–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Palmqvist R, Stenling R, Oberg A, Landberg G. Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer. 1998;34:1575–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Marsh KL, Varley JM. Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry. Br J Cancer. 1998;77:1460–8.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005–11.PubMedGoogle Scholar
  14. 14.
    Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 2003;278:30339–47.CrossRefPubMedGoogle Scholar
  16. 16.
    Le Marchand L, Seifried A, Lum-Jones A, Donlon T, Wilkens LR. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. J Am Med Assoc. 2003;290:2843–8.CrossRefGoogle Scholar
  17. 17.
    Zheng Y, Shen H, Sturgis EM, et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case–control study. Carcinogenesis. 2001;22:1195–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang L, Habuchi T, Takahashi T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang L, Habuchi T, Mitsumori K, et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer. 2003;103:116–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Akkiz H, Bayram S, Bekar A, Akgöllü E, Ozdil B. Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case–control study. Cancer Epidemiol. 2010;34:298–302.CrossRefPubMedGoogle Scholar
  21. 21.
    Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266:1821–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Donnellan R, Chetty R. Function of a human cyclin gene as an oncogene. Mol Pathol. 1998;51:1–7.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Zhang YJ, Jiang W, Chen CJ, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993;196:1010–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994;54:3107–10.PubMedGoogle Scholar
  26. 26.
    Comstock CE, Augello MA, Benito RP, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res. 2009;15:5338–49.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Yu J, Habuchi T, Tsuchiya N, et al. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol. 2004;172:2410–3.CrossRefPubMedGoogle Scholar
  28. 28.
    Krippl P, Langsenlehner U, Renner W, et al. The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat. 2003;82:165–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Yu C, Lu W, Tan W, et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2003;12:176.PubMedGoogle Scholar
  30. 30.
    Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Zhang YJ, Chen SY, Chen CJ, Santella RM. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog. 2002;33:125–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Wang X, Zhang X, Qiu B, et al. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Buch S, Zhu B, Davis AG, et al. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog. 2005;42:222–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Bala S, Peltomäki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61:6042–5.PubMedGoogle Scholar
  35. 35.
    Holley SL, Parkes G, Matthias C, et al. Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol. 2001;159:1917–24.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Zhangyong Hu
    • 1
  • Zhipeng Zhou
    • 2
  • Guolian Xiong
    • 3
  • Yali Wang
    • 3
  • Yi Lai
    • 4
  • Lan Deng
    • 3
  • Jinliang Yang
    • 1
  1. 1.State Key Laboratory of Biotherapy and Cancer Center, West China HospitalWest China Medical School, Sichuan UniversityChengduPeople’s Republic of China
  2. 2.Department of Liver and Vascular SurgeryWest China Hospital, Sichuan UniversityChengduPeople’s Republic of China
  3. 3.Department of Infectious DiseaseThe First Affiliated Hospital of Chengdu Medical CollegeChengduPeople’s Republic of China
  4. 4.Department of Clinical Laboratory MedicineChengdu Medical CollegeChengduPeople’s Republic of China

Personalised recommendations